Combination of the mTOR Inhibitor Ridaforolimus and the Anti-IGF1R Monoclonal Antibody Dalotuzumab: Preclinical Characterization and Phase I Clinical Trial

Di Cosimo, S.; Sathyanarayanan, S.; Bendell, J. C.; Cervantes, A.; Stein, M. N.; Brana, I.; Roda, D.; Haines, B. B.; Zhang, T.; Winter, C. G.; Jha, S.; Xu, Y.; Frazier, J.; Klinghoffer, R. A.; Leighton-Swayze, A.; Song, Y.; Ebbinghaus, S.; Baselga, J.

期刊名称Clinical Cancer Research
作者Di Cosimo, S.; Sathyanarayanan, S.; Bendell, J. C.; Cervantes, A.; Stein, M. N.; Brana, I.; Roda, D.; Haines, B. B.; Zhang, T.; Winter, C. G.; Jha, S.; Xu, Y.; Frazier, J.; Klinghoffer, R. A.; Leighton-Swayze, A.; Song, Y.; Ebbinghaus, S.; Baselga, J.
卷第21卷
期第1期
印刷ISSN1078-0432
电子ISSN1557-3265
文件大小725.93KB
发表时间2015-01-01
DOI10.1158/1078-0432.ccr-14-0940
页码49-59

发现好书期刊，享受阅读乐趣

Combination of the mTOR Inhibitor Ridaforolimus and the Anti-IGF1R Monoclonal Antibody Dalotuzumab: Preclinical Characterization and Phase I Clinical Trial